Get started
Author

Elizabeth Thacker

Observed name: E. A. Thacker
Observed institution: Duke Medical Center
ORCID: 0009-0008-1560-5260
Observed ORCID: 0009-0008-1560-5260
OpenAlex ID: A5031238770
Mitochondrial DNA damage as a potential biomarker of LRRK2 kinase activity in LRRK2 Parkinson’s disease
2020 · C. P. Gonzalez-Hunt, E. A. Thacker, et al. · Scientific Reports · 39
PDF
Impact of Molecular Features of Diffuse Large B-Cell Lymphoma on Treatment Outcomes with Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy
2021 · Brian T. Hill, Caroline J Roth, et al. · Blood · 13
Progression of follicular lymphoma and related entities: Report from the 2021 SH/EAHP Workshop
2023 · Amy S Duffield, Ahmet Dogan, et al. · American Journal of Clinical Pathology · 9
PDF
LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair
2023 · Jianli Zhou, Drew Sturtevant, et al. · Oncotarget · 4
PDF
Transformations of marginal zone lymphomas and lymphoplasmacytic lymphomas: Report from the 2021 SH/EAHP Workshop
2023 · James R Cook, Catalina Amador, et al. · American Journal of Clinical Pathology · 4
Clinical Validation of Duoseq, a Novel Assay for Clinical DNA and RNA Sequencing
2025 · Elizabeth Thacker, Lanie Happ, et al. · Journal of Molecular Diagnostics · 2
Characterising the genomic landscape of two clinical risk groups in CD30+ T-cell lymphoproliferative disorders with cutaneous involvement: a multi-institutional retrospective study
2026 · Leonardo P.A. Biral, Veronica Russell, et al. · EBioMedicine · 1
Molecular and Clinical Determinants of CAR-T Therapy Response in DLBCL
2024 · Devang Thakkar, Brian T. Hill, et al. · Blood · 1
Development and validation of Duoseq as a novel diagnostic and companion assay for lymphoma and other cancers.
2022 · Chrissie Rozzi, Stacey O'Neill, et al. · Journal of Clinical Oncology · 1
Primary mediastinal large B-cell lymphoma genomic profiling demonstrates thymic B-cell identity and frequent aberrant somatic hypermutation
2026 · Rebecca J. Leeman-Neill, Leonardo P.A. Biral, et al. · Cancer Research Communications
Data from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Supplementary Figure S4 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Figure 3 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Supplementary Figure S2 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Supplementary Figure S3 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Table 1 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Supplementary Figure S1 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Figure 2 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
CRC-25-0834_supplementary_table_ST1-ST4 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Supplementary Figure S5 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Figure 1 from Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al.
Elucidating the Gene Expression Signature of Rosai–Dorfman Disease: A Study from the Atlas of Blood Cancer Genomes Initiative
2026 · Sheren Younes, Fadzai Chinyengetere, et al. · Cancer Research Communications
PDF
Genomic landscape of mycosis fungoides
2025 · Fadzai Chinyengetere, Leonardo P. A. Biral, et al. · Blood
PDF
Unraveling the Transcriptional Landscape of Nodular Lymphocyte-Predominant Hodgkin Lymphoma and T-Cell/Histiocyte Rich Large B-Cell Lymphoma: Impact of Tumor Microenvironment and Checkpoint Gene Expression
2023 · Ilja Kalashnikov, Veronica Russell, et al. · Blood
PDF
Analytical and Clinical Validation of Duoseq, a Novel Assay for Rapid, on-Site Clinical DNA and RNA Sequencing of Hematologic Malignancies
2023 · Eric D. Hsi, Magdalena Czader, et al. · Blood
PDF
Works count: 29
Citation count: 74
H-index: 4
I10-index: 2
Year
Topic
Type